Physician profile
Dinara Rose
NPI 1972942936
$7,462.93
in general payments reported to CMS, 2019-2025
42 companies · $963 in 2025
The $963 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,134 · 2021: $1,352 · 2022: $983 · 2023: $810 · 2024: $813 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,009.31 | 2020-2025 | Vraylar, Qulipta, Synthroid |
| Astrazeneca Pharmaceuticals LP | $904.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $715.29 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.92 | 2019-2025 | Jardiance |
| Amgen INC. | $530.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $479.04 | 2019-2022 | |
| Glaxosmithkline, LLC. | $380.85 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $356.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.93 | 2022-2025 | |
| Optinose US, INC. | $145.15 | 2019-2022 | |
| Pfizer INC. | $85.02 | 2020-2021 | |
| Exact Sciences Corporation | $83.49 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $76.39 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.50 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinara Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.